Select Page

Anti-Human IL-6 (Sarilumab) – HRP – 100 µg

100 μg



ApplicationELISA, FA, FC
ConjugateHorseradish Peroxidase (HRPO)
IsotypeHuman IgG1κ
Species ReactivityHuman
FormulationThis HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase)
Research AreaCancer, Immunology
Description/BackgroundIL-6 and its signaling pathway play a part in immune response regulation, inflammation, and hematopoiesis.2 Sarilumab is a research-grade recombinant human monoclonal IL-6 receptor antagonist. It specifically binds to both the transmembrane and soluble forms of the IL-6 receptor, thus inhibiting IL-6–mediated cis and trans-signaling in a dose-dependent manner.1 Therapeutic Sarilumab, also known by the trade name Kevzara, is currently used to treat Rheumatoid Arthritis1, however, as of March 2020, The Feinstein Institute of Northwell Health publicized a study on "a human antibody that may prevent the activity" of IL-6 for the treatment of COVID-19.3 Anti-Human IL-6 (Sarilumab) utilizes the same variable regions from the therapeutic antibody Sarilumab making it ideal for research projects.
Storage TemperatureThis horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze.
ProtocolsELISA, FA, FC
Clone NumberHu137
Concentration0.5 mg/ml
Regulatory StatementFor Research Use Only. Not for use in diagnostic procedures.
100 μg